article thumbnail

Three Big Questions for Stage 3 & Patient Engagement

Chilmark Research

For many, the delay of Stage 3 of the Meaningful Use program evoked a collective sigh of relief, providing a much-needed extra year to focus on the challenging requirements for patient engagement and interoperability. Each of these use cases brings with it a unique set of programmatic and technical components.

article thumbnail

FDA and Digital Health Regulation

Health Blawg

The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices. The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Healthcare CIOs Face New Pressures and Novel Opportunities

David Chou

Besides focusing on EHR optimization, organizations see automation as a way to become more efficient and cut costs, Chou adds. For several years, CIOs focused on implementing EHRs and meeting Meaningful Use requirements, she says. Optimizing the EHR to improve clinician productivity 2.

EHR 40
article thumbnail

FDA and Digital Health Regulation

Health Blawg

The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices. The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices.

article thumbnail

FDA and Digital Health Regulation

Health Blawg

The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices. The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices.

article thumbnail

FDA and Digital Health Regulation

Health Blawg

The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices. The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices.

article thumbnail

FDA and Digital Health Regulation

Health Blawg

The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices. The agency has a history of articulating its position on where the line is to be drawn, on how it is to exercise its discretion in regulating devices.